Home › Trial NCT03746249
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
- Trial IDNCT03746249
- StatusWithdrawn
- PhasePhase 2
- Study typeInterventional
- SponsorSun Yat-sen University
- Enrollment—
- Start date2018-12-17
- ConditionsHepatocellular Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.